Correlation between the abundance of EGFR T790M mutations and the efficacy of EGFR and TKI in primary plasma ctDNA of non-small cell lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029773

Enrollment

Unknown

Registered

2020-02-13

Start date

2018-06-08

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Case series:Nil

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. non-small cell lung cancer confirmed by cytology or histology; 2. ECoG score 0-2; 3. patients with stage IIIB to stage IV according to the latest TNM; 4. no tumor related treatment; 5. aged over 18 years; 6. at least one measurable lesion; 7. the sensitive EGFR gene mutation type of EGFR TKI was confirmed by arms or ngs in histology and cytology; 8. at least 10 paraffin sections (more than 30% tumor cells) and 10 ml blood samples can be collected at baseline; 9. sign informed consent.

Exclusion criteria

Exclusion criteria: 1. any signs of toxic or uncontrolled systemic disease considered in the study that may significantly alter the patient's risk / benefit balance; 2. patients do not agree to use the existing medical data for scientific research and sharing with national big data; 3. samples with untrue and incomplete registration form information records; 4. unable to tolerate the first generation of EGFR TKI treatment.

Design outcomes

Primary

Measure	Time frame
progression free survival, PFS;	—

Secondary

Measure	Time frame
overall survival, OS;objective response rate, ORR;disease control rate, DCR;	—

Countries

China

Contacts

Public ContactMa Li

Beijing Chest Hospital, Capital Medical University

silenceli2013@163.com+86 15810209360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026